TOP - February 2017, Vol 10, No 1
Using Montelukast to Reduce Infusion Reactions in Patients with Relapsed or Refractory Multiple Myeloma
Daratumumab therapy is successful in patients with multiple myeloma who have received ≥3 previous lines of therapy, including a proteasome inhibitor and an immunomodulatory drug (IMiD), or whose disease is double-refractory to those other drugs.
The Use of Early Response Can Guide Treatment Selection in Patients with Newly Diagnosed Multiple Myeloma
In 2015, the combination of bortezomib, lenalidomide, and dexamethasone was shown to improve survival outcomes versus lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma. However, this triplet therapy also increased patients’ risk for severe peripheral neuropathy.
Long-Term Analysis of the CASTOR Trial: Adding Daratumumab to Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Daratumumab is a human CD38 IgGκ monoclonal antibody that demonstrated significant activity and a manageable safety profile when used in combination with bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.
Real-World Evidence Regarding Newer Treatment Options, Overall Survival, and Healthcare Costs in Patients with Multiple Myeloma
Adding Daratumumab to Lenalidomide and Dexamethasone in Previously Treated Patients with Relapsed or Refractory Multiple Myeloma Improves Outcomes
Daratumumab demonstrated superior efficacy when combined with lenalidomide plus dexamethasone compared with lenalidomide and dexamethasone alone in a prespecified interim analysis of a randomized phase 3 clinical trial of patients with relapsed or refractory multiple myeloma.
A persistent medication safety issue is getting the attention it has long deserved. In an effort to save lives related to the accidental intrathecal dosing of vincristine, the National Comprehensive Cancer Network (NCCN) has launched a program called “Just Bag It: The NCCN Campaign for Safe Handling of Vincristine."
The relative lack of progress in the treatment of malignant pleural mesothelioma is in marked contrast to developments in the treatment of lung cancer overall, but several ongoing studies using different immune-based therapies have shown promise in the treatment of this type of cancer.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented by Paolo Bossi, MD, at the recent European Society for Medical Oncology Congress.
High Rates of Vancomycin-Resistant Enterococci Bacteremia Observed in Patients Receiving Allogeneic Hematopoietic Stem-Cell Transplant
Page 2 of 3
Results 11 - 20 of 28
Results 11 - 20 of 28